StemCell Therapy

Travel and movement restrictions in Croatia are changing by the day - even by the hour - as the country fights to reign in COVID-19. 235 cases of coronavirus are currently confirmed in Croatia. Read on to find the latest travel (within, into and out of Croatia) information as of March 21, 2020.

TRAVEL AND MOVEMENT WITHIN CROATIA

New rules have been implemented by the Croatian government regarding civilian, vehicular and sea transport throughout the country.

Thefollowingcivilian movement restrictions are currently implemented across Croatia:

Gatherings of five or more people are banned

A two-metre distance must be kept between individuals outside of the home (both indoors and outdoors)

Loitering is prohibited in public areas including

* Streets

* Squares

* Rivieras

* Parks

* All other public surfaces on which a large number of people can gather

The following are still open

* Grocery stores* Grocery and hygienic product stores* Markets and fish markets* Specialized stores for medicine (pharmacies)* Specialized stores for veterinary-medical products* Agriculture-based pharmacies* Gas stations* Kiosks* Bakeries* Dry cleaners* Specialized stores with orthopedic and other assistance-based products* Specialized stores with equipment for children* Specialized stores with food for animals* Issuance of construction materials per retail order* Logistic and distribution centres for food, beverages and hygiene products* Wholesalers

The followingare closed

* All cultural establishments (museums, theaters, cinemas, libraries, reading rooms), exhibitions, shows and fairs* All customer service establishments (including cafs and restaurants), with the exception of food preparation and delivery services, accommodation services, and soup and student kitchens* All service establishments which entail close contact with customers (for example, hairdressers, beauty salons, barber shops, nail salons, massage parlors, saunas, swimming pools)* All sports competitions, organized trainings, gyms, sports centers, fitness and recreation centers* Childrens and other workshops and organized dance schools* Driving schools and language schools* Religious gatherings

Leaving the house should be kept to a minimumand only done when necessary, and in accordance with new rules.

The followingpublic transportrestrictions are currently implemented across Croatia:

* Public transportwithin and between cities and regions (excludingtaxis)

* International public transport

* All bus, tram and train transport

* Other public vehicles such as cable cars and funiculars

The following roadwayrestrictions are currently implemented across Croatia for civilian drivers:

* Novska jug

* Novska sjever

* Kozjak jug

* Prokljan sjever

* Dragani sjever

* Dragani jug

* Bava

* Ravna Gora

Follow the website of the Croatian Automobile Club, aka HAK (Croatia's equivalent to the USA's AAA or UK's AA) for full traffic information in English here.

The following sea travelrestrictions are currently implemented across Croatia:

* 310 Mali Losinj - (Unije) - Srakane Vele - Susak) and vice versa

* 311 Ilovik - Mrtvaka and vice versa

* 405 Rava - (Mala Rava - Veli I - Mali I) - Zadar and vice versa

* 415 Vrgada - Pakotane - (Biograd) and vice versa

* 501 Krpanj - Brodarica

* 505 (Vodice - Prvi epurine - Prvi Luka - Zlarin) - ibenik and vice versa

* 612 Komia - Bievo and vice versa

* 807 Suura - Lopud - Koloep - Dubrovnik

* Croatian and foreign nationals residing on the islands or in the Peljeac peninsula

* Vehicles belonging to or leased by island residents(adequately registeredper jurisdictional regulations)

* Public health employees

* Public service employees (including police officers, firefighters, armed forces, port authorities, post office staff, utility staff) and their official vehicles

* Store supply staff as approved by the Civil Protection Headquarters and their official vehicles as required

* Delivery service personnel and their vehicles

* Legal staff and their official vehiclesas approved by the Civil Protection Headquarters

For air travel information, check directly with airlines.

Croatia has nine civilian airports (see list below). Some airports offer information on their pages, but for specific air travel information (flight times, availability, cancellations, delays, refunds), check directly with airlines.

Anyonewho breaks restrictions is subject to fines and other potential punishment. Fines can reach up to120,000 HRK for repeat offenders.Police forces across the country will be monitoring streets and public areas to make sure rules are being followed. Maja Grba Bujevi, head of the Crisis Headquarters of the Ministry of Health,warned today that stricter measures are ahead if citizens disobey rules.

CROSS-BORDER TRAVEL

As of Tuesday, March 17, the European Union has closed its borders to all non-European Union citizens for a 30-day period. Travel within the EU is permitted or restricted on a country-by-country basis.

For travelto and from other EU countries from Croatia:

Croatia is allowing EU citizens to return to their countries of citizenship.Croatian citizens are allowed entry back into Croatia. EU citizens will be allowed entry to Croatia only inspecial circumstances (for example, health workers, researchers, diplomats, police officers, civilian safety teams, military personnel), as determined by the Croatian Institute of Public Health. Additional information regarding Croatia and its bordering countries can be found here.

Everyone(citizens and non-citizens) entering Croatia is subject to specificmeasures (which include isolation in a government facility or self-isolation), asrequiredby the Croatian Institute of Public Health.

For international travelto and from Croatia:

International bus and train lines have been stopped. International air travel is ongoingbut varies from case to case, so check flight information directly with airlines.

As of March 12, 2020, travellers to Croatia from specially-defined COVID-19-affected areas arerequired to spend 14 days in government quarantine facilities. Thedefined areas are

* China: Hubei province, including the city of Wuhan

* Germany:the County of Heinsberg in the state of North Rhine-Westphalia

* Iran

* Italy

* South Korea:the city of Daegu and the County of Cheongdo

The Croatian Ministry of Health has also implemented monitoring and self-isolation measures for travellersfrom any COVID-19-affected countries including

* Albania* Algeria* Andorra* Australia* Austria* Bahrain* Bangladesh* Belarus* Belgium* Brazil* Bulgaria* Cambodia* Cameroon* Canada* Chile* China (except region listed above)* Costa Rica* Cyprus* Czech Republic* Denmark* Ecuador* Egypt* Finland* France* Germany

* Greece

* Hong Kong* Hungary* Iceland* India* Indonesia* Iraq* Ireland* Israel* Japan* Lebanon* Liechtenstein* Luxembourg* Malaysia* Maldives* Malta* Monaco* Montenegro* Netherlands* New Zealand* North Macedonia* Norway* Pakistan* Peru* Philippines* Poland* Portugal* Romania* San Marino* Singapore* Slovakia* Slovenia* South Korea (except region listed above)* Spain* Sweden* Switzerland* Thailand* Turkey* Ukraine* United Arab Emirates* United Kingdom* United States of America* Vietnam

Travellers from these countries (even if theyshow noCOVID-19 symptoms)mustself-isolate for 14 days and contact the nearest epidemiologist for further instructions (which may include hospitalization if theyshow symptoms).

Alist of epidemiologist health institution contactsby Croatian county can be found here.

For non-EU citizens in Croatia, and for details about travelling in and out of the EU, consult your local embassies and specific government websites for travel and contact information.

The recommendation of the Croatian Ministry of Foreign and European Affairs is to delayany and all travels if possible.

Time Out (In) Croatia wishes everyone health, hope and healing.We will get through this!

See original here:
ALL YOU NEED TO KNOW: Travelling within, into and out of Croatia - March 21, 2020 - Time Out

DUBLIN, March 20, 2020 /PRNewswire/ -- The "Population Health Management Market by Component (Software, Services), Mode of Delivery (On-premise Mode of Delivery, Cloud-based Mode of Delivery), End User (Healthcare Providers, Healthcare Payers, Government Bodies)] - Global Forecasts to 2025" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global population health management market is projected to reach USD 39.4 billion by 2025 from USD 22.9 billion in 2020, at a CAGR of 11.5% during the forecast period.

Government mandates and support for healthcare IT solutions, increasing use of big data analytics, and the need to curtail the escalating healthcare costs are the key factors driving the growth of the population health management market. In addition, emerging economies (such as Brazil, Russia, India, South Korea, and China), increasing focus on personalized medicine, and rising focus on value-based medicine are expected to offer lucrative growth opportunities for market players during the forecast period. However, data breaches, lack of skilled analysts, and interoperability issues are adversely impacting the growth of this market.

The software segment accounted for the larger share of the population health management market, by component, in 2019

On the basis of component, the population health management market is segmented into software and services. The software segment accounted for the largest share of the population health management market in 2019. Technological advancements in IT solutions and big data analytics, growth of cloud computing, and increasing penetration of the Internet across the globe are some of the key factors driving the demand for software-based HCIT solutions. Moreover, the adoption of population health management software to coordinate care processes is expected to increase in the coming years owing to its ability to reduce readmissions, increase cost-effectiveness, and enhance patient engagement.

By mode of delivery, the on-premise mode of delivery segment accounted for the largest market share in 2019

Population health management solutions are delivered to end users through the on-premise and cloud-based modes of delivery. The on-premise solutions segment accounted for the larger market share in 2019. The advantages offered by the on-premise mode of delivery, and the ability to reuse existing servers and storage hardware are supporting its increased adoption in the population health management market.

By end user, the healthcare providers segment accounted for the largest market share in 2019

On the basis of end user, the population health management market is segmented into healthcare providers, healthcare payers, and other end users. In 2019, the healthcare providers segment accounted for the largest share of the population health management market. The advantages offered by PHM solutions, growing pool of patients, increasing load on hospitals to integrate and manage patient data in a more efficient way, and the growing need to improve the affordability and accessibility of healthcare services are propelling the growth of the PHM solutions market for healthcare providers.

APAC is the fastest-growing market for population health management.

The population health management market in the APAC is expected to witness the highest CAGR during the forecast period. The growth of the Asia Pacific population health management market is driven by the rising medical tourism, the implementation of new ICT guidelines in Japan, investments and reforms to modernize China's healthcare infrastructure, the rapidly growing healthcare industry in India, and the implementation of IT programs in Australia and New Zealand. In addition, government initiatives for the adoption of HCIT, the growing geriatric population, rising prevalence of chronic diseases, increasing healthcare expenditure, and the rising purchasing power of consumers are also expected to support market growth in this region.

Story continues

Key Topics Covered

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights 4.1 Market Overview4.2 North America: Market, By Component & Country (2019)4.3 Population Health Management Market: Geographic Growth Opportunities

5 Market Overview 5.1 Introduction5.2 Market Dynamics5.2.1 Drivers5.2.1.1 Government Mandates & Support for Healthcare IT Solutions5.2.1.2 Increasing Use of Big Data Analytics5.2.1.3 Need to Curtail Escalating Healthcare Costs5.2.2 Restraints5.2.2.1 Huge Investments in Infrastructure to Set Up A Robust PHM Program5.2.3 Opportunities5.2.3.1 Emerging Markets5.2.3.2 Rising Focus on Personalized Medicine5.2.3.3 Increasing Focus on Value-Based Medicine5.2.4 Challenges5.2.4.1 Data Breaches5.2.4.2 Lack of Data Management Capabilities and Skilled Analysts5.2.4.3 Interoperability Issues

6 Population Health Management Market, By Component 6.1 Introduction6.2 Software6.2.1 Software is the Largest Component Segment of the Market6.3 Services6.3.1 Increasing Adoption of PHM Solutions & Indispensable & Recurring Nature of Services to Drive Market Growth

7 Population Health Management Market, By Mode of Delivery 7.1 Introduction7.2 On-Premise Mode of Delivery7.2.1 On-Premise Mode of Delivery Segment Accounted for the Largest Market Share in 20197.3 Cloud-Based Mode of Delivery7.3.1 Cloud-Based Mode of Delivery Segment to Register the Highest Growth in the PHM Market Between 2020 & 2025

8 Population Health Management Market, By End User 8.1 Introduction8.2 Healthcare Providers8.2.1 Growing Need to Improve the Profitability of Healthcare Operations is Driving the Use of PHM Solutions Among These End Users8.3 Healthcare Payers8.3.1 Increased Focus on Outcome-Based Payment Models has Driven the Demand for PHM Solutions Among Healthcare Payers8.4 Other End Users

9 Population Health Management Market, By Region 9.1 Introduction9.2 North America9.2.1 US9.2.1.1 The US is the Largest Market for Population Health Management Solutions9.2.2 Canada9.2.2.1 Deployment of Digital Health Initiatives is Boosting Market Growth in Canada9.3 Europe9.3.1 Germany9.3.1.1 Germany Dominates the European Population Health Management Market9.3.2 UK9.3.2.1 Increasing Public-Private Initiatives to Support the Adoption of PHM Solutions in the Country9.3.3 France9.3.3.1 Rising Geriatric Population and the Increasing Patient Volume for Various Chronic and Age-Related Conditions to Drive Market Growth9.3.4 Italy9.3.4.1 Government Initiatives to Support Market Growth in Italy9.3.5 Spain9.3.5.1 Increasing Adoption of PHM Solutions to Support Market Growth in Spain9.3.6 Rest of Europe9.4 Asia Pacific9.4.1 Japan9.4.1.1 Japan Accounted for the Largest Share of the APAC PHM Market in 20199.4.2 China9.4.2.1 Strong Government Support in China is Driving the PHM Market9.4.3 India9.4.3.1 Growing Volume of Patient Data Generated Within Healthcare Systems to Propel the Market for PHM Solutions in India9.4.4 Rest of Asia Pacific (RoAPAC)9.5 Rest of the World9.5.1 Latin America9.5.1.1 Brazil, Argentina, and Mexico are Emerging Healthcare Markets in Latin America9.5.2 Middle East & Africa9.5.2.1 Increasing Investments in Modernizing Healthcare Systems are Propelling Market Growth

10 Competitive Landscape 10.1 Introduction10.2 Competitive Leadership Mapping (Overall Market)10.2.1 Visionary Leaders10.2.2 Innovators10.2.3 Dynamic Differentiators10.2.4 Emerging Companies10.3 Competitive Scenario

11 Company Profiles 11.1 Cerner Corporation11.2 Epic Systems Corporation11.3 Koninklijke Philips11.4 I2I Population Health11.5 Health Catalyst11.6 Optum (Part of Unitedhealth Group)11.7 Enli Health Intelligence11.8 Eclinicalworks11.9 Allscripts Healthcare Solutions11.1 IBM Corporation11.11 Healthec, LLC11.12 Medecision11.13 Arcadia11.14 Athenahealth11.15 Cotiviti (Verscend Technologies)11.16 Nextgen Healthcare Inc.11.17 Conifer Health Solutions11.18 SPH Analytics11.19 Lightbeam Health Solutions11.20 Innovaccer

For more information about this report visit https://www.researchandmarkets.com/r/q02un0

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/population-health-management-industry-forecast-to-2025-a-39-billion-landscape-opportunity-301027444.html

SOURCE Research and Markets

See more here:
Population Health Management Industry, Forecast to 2025: A $39+ Billion Landscape Opportunity - Yahoo Finance

Verified Market Research recently published a research report titled, Personalized Medicine Market Study Report 2020. The research report is created based on historical and forecast data derived from researchers using primary and secondary methods. The Personalized Medicine market is one of the fastest-growing markets and is expected to witness substantial growth in the forecast years. Reader are provided easy access to thorough analysis on the various aspects such as opportunities and restraints affecting the market. The report clearly explains the trajectory this market will take in the forecast years.

Global Personalized Medicine Market was valued at USD 96.97 Billion in 2018 and is expected to witness a growth of 10.67% from 2019-2026 and reach USD 217.90 Billion by 2026.

Get | Download Sample Copy @ https://www.verifiedmarketresearch.com/download-sample/?rid=7106&utm_source=BCC&utm_medium=002

Personalized Medicine Market Leading Players:

Personalized Medicine Market: Competitive Landscape

This section of the report provides complete information about the various manufacturers in the market. The major manufacturers to which the report refers hold a large proportion that require a microscopic appearance. It provides important information about the different strategies of these manufacturers to combat competition and to expand their presence in the market. In addition, the current trends of the manufacturers are checked in order to innovate their product for the future. This report is intended to help the reader understand the market and make business decisions accordingly.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7106&utm_source=BCC&utm_medium=002

Table of Contents :

Executive Summary: It includes key trends of the Personalized Medicine market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the Personalized Medicine market based on production and revenue.

Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.

Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Personalized Medicine market.

Market Segments: This part of the report discusses about product type and application segments of the Personalized Medicine market based on market share, CAGR, market size, and various other factors.

Research Methodology: This section discusses about the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.

Why to Buy this Report?

The report is a perfect example of a detailed and meticulously prepared research study on the Personalized Medicine market. It can be customized as per the requirements of the client. It not only caters to market players but also stakeholders and key decision makers looking for extensive research and analysis on the Personalized Medicine market.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/global-personalized-medicine-market-size-and-forecast-to-2026/?utm_source=BCC&utm_medium=002

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes; Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: sales@verifiedmarketresearch.com

Tags: Personalized Medicine Market Size, Personalized Medicine Market Trends, Personalized Medicine Market Forecast, Personalized Medicine Market Growth, Personalized Medicine Market Analysis

Read more from the original source:
Personalized Medicine Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - NJ MMA News

This is the first study to demonstrate an overall survival benefit from precision medicine in pancreatic cancer patients.

The study analyzed more than 1,000 pancreatic cancer patients enrolled in PanCAN's Know Your Tumor precision medicine service, powered by Perthera, and found those patients who received matched therapies following molecular profiling of their tumor, using the Perthera Platform, saw an overall survival benefit of one year longer than those who did not.

Pancreatic cancer is the world's toughest cancer with an overall five-year survival rate of just 10 percent. It is currently the third leading cause of cancer-related death in the U.S., underscoring the urgent need for new treatment options and research discoveries in this space.

When PanCAN's Know Your Tumor service was started with Perthera in 2014, key precision medicine resources such as molecular profiling were rarely offered to patients with pancreatic cancer because many doctors assumed there wasn't anything actionable to be found. The study showed that approximately 25 percent of pancreatic cancer patients have an actionable alteration. It also underscores the significance of the most recent National Comprehensive Cancer Network (NCCN) guidelines that state that every patient with pancreatic cancer should get testing - both molecular profiling of their tumor and germline (genetic) testing for alterations they were born with.

The results of this study will help re-write the future for cancer patients for years to come, said Gary Gregory, CEO & President, Perthera, Inc. Increasing patient survival is the cornerstone of the work that PanCAN has spearheaded with Perthera across the U.S. This study clearly proves that, by utilizing precisely matched therapies provided by molecular profiling, along with Therapeutic Intelligence and a Molecular Tumor Board, patients with pancreatic cancer have experienced significant increases in both overall and progression-free survival.

This is critical news for pancreatic cancer patients. Every tumor is different and through this study, we know that patients who get tested and receive treatment based on their tumor's biological characteristics are living longer, said Lynn Matrisian, PhD, MBA, Chief Science Officer at PanCAN and an author on the paper. It is a strong reminder to healthcare professionals to offer tumor profiling to all their pancreatic cancer patients. And it will further provide an incentive to the scientific community to pursue new targeted treatments for even more pancreatic cancer patients.

Several of the molecularly-matched therapies given have now been FDA approved for patients with pancreatic cancer based on select biomarkers. Adopting molecular profiling into routine practice will be critically important to making sure these patients do not miss out on life-extending opportunities that can now be covered by insurance. These real-world outcomes suggest that the adoption of a precision medicine platform can have a substantial impact on survival in patients with pancreatic cancer, and that molecularly-guided treatments targeting oncogenic drivers and the DNA damage repair pathway warrant further prospective evaluation, said Mike Pishvaian, MD, PhD, Perthera's Chief Medical Officer GI Medical Oncology, University of Texas, MD Anderson Cancer Center, Johns Hopkins Medicine.

PanCAN recommends that all pancreatic cancer patients undergo testing of both their tumor tissue (molecular profiling) and blood or saliva for genetic (germline) changes to determine if they have an actionable alteration and to identify treatment options for that patient. Patients can enroll in PanCAN's free Know Your Tumor precision medicine service today, as well as receive free, in-depth, and personalized resources and information on the disease through PanCAN's Patient Central.

The Perthera Platform has been proven to capitalize upon actionable alterations and improve patient outcomes across numerous, peer reviewed clinical publications. The Perthera Platform, which has been used by over 250 cancer treatment sites across the U.S., captures a patient's entire medical and treatment history, as well as their multi-omic molecular profile, to create a personalized treatment plan, that enable physicians to effectively harness the power of precision medicine.

More here:
New Research Reveals Pancreatic Cancer Patients Who Receive Precision Medicine Live An Average Of One Year Longer Than Those Who Do Not #47579 - New...

President Donald Trump has repeatedly said that the US is working to develop a vaccine for Covid-19, the disease caused by the novel coronavirus, as quickly as possible. But one of his own administrations policies appears to be standing in the way of at least one scientist.

According to a report by the Washington Posts Amy Goldstein, Kim Hasenkrug, an immunologist at the National Institutes of Healths Rocky Mountain Laboratories in Montana, wants to test potential treatments for Covid-19 in mice with humanized lungs. But as the Post first reported, the work is being held up by officials at the Department of Health and Human Services due to a 2019 ban on NIH scientists using donated fetal tissue from abortions in their research.

While fetal tissue isnt typically used to develop actual therapies or treatments, it has one particularly key use for researchers: the ability to create mice with human tissue suitable for medical testing. Mice, generally, have similar immune systems to humans, making them particularly useful for early medical testing.

Humanized mice have been key to developing several important medical treatments for diseases like the Zika virus or HIV/AIDS, which was Hasenkrugs previous research focus. The calculation is simple. You cant test certain treatments without humanized mice, and you cant get humanized mice without fetal tissue.

There are, of course, many avenues of research using other kinds of tissue, but fetal cells can rapidly divide, grow, and adapt to new environments in ways that make them the gold standard for some disease research. And in other research areas, we dont yet know if there is anything that could substitute, R. Alta Charo, professor of law and bioethics at the University of Wisconsin at Madison, wrote in the New England Journal of Medicine in 2015.

And as the Posts Goldstein noted, scientists have already shown that humanized mice could make good test subjects for coronavirus treatments specifically:

Just months ago, before the new coronavirus began to infect people around the world, other U.S. scientists made two highly relevant discoveries. They found that specialized mice could be transplanted with human fetal tissue that develops into lungs the part of the body the new coronavirus invades. These humanized mice, they also found, could then be infected with coronaviruses to which ordinary mice are not susceptible closely related to the one that causes the new disease, Covid-19.

Outside researchers have offered the mice to Hasenkrug for coronavirus research. But so far, Hasenkrug and other government researchers havent been allowed to obtain the mice they need to perform testing, the Post reported, thanks to a June 2019 HHS directive banning fetal tissue research for those employed by the government.

Caitlin Oakley, a HHS spokesperson, told the Post that no decision has been made about Hasenkrugs request. A separate HHS spokesperson confirmed that in a statement to Vox.

The spokesperson also pointed to an HHS statement from last June detailing the administrations policy on fetal tissue research. Promoting the dignity of human life from conception to natural death is one of the very top priorities of President Trumps administration, reads the statement.

Hasenkrug, and the potentially millions of Americans who may benefit from his research, now find themselves caught in a deeply divisive political issue thats been years in the making.

The US government had funded fetal tissue research efforts since the 1950s and for nearly as long, anti-abortion activists have opposed the practice.

In the Trump era, they finally found an administration ready to listen.

In 2018, the US government spent $115 million on about 173 research projects utilizing fetal tissue, a third of which were devoted to developing therapies for HIV/AIDS.

Research using fetal tissue has led to the development of vaccines such as those for polio, rubella, and measles, the International Society for Stem Cell Research (ISSCR) said in a statement last September. Fetal tissue is still helping advance science, with research underway using cells from fetal tissue to evaluate conditions including Parkinsons disease, ALS, and spinal cord injury. Fetal tissue is also necessary for the development of potential treatments for Zika virus and HIV/AIDS.

But anti-abortion activists argue it incentivizes abortion providers to perform more abortions in order to procure more tissue they could sell to third-party companies, which then provide the tissue directly to researchers. Fetal tissue procurement has been heavily regulated since enactment of the NIH Revitalization Act of 1993, which states that profits cannot be made in the transfer or acceptance of fetal tissue for research purposes.

That hasnt stopped anti-abortion activists from continuing to call into question the ethics of abortion providers or procurement companies. In 2000, the anti-abortion rights group Life Dynamics seemingly began the practice of releasing false or deceptively edited videos targeting the fetal tissue sales process. The main source in their videos was found to be not credible.

The George W. Bush administration did not take action against fetal tissue research, instead enacting restrictions on stem cell research derived from embryos in an August 2001 executive order. Those restrictions were later rolled back by an executive order from President Barack Obama in 2009.

More recently, the anti-abortion rights group Center for Medical Progress, run by activist David Daleiden, infamously released heavily edited videos appearing to show a Planned Parenthood employee negotiating prices for fetal tissue, and CMP accused the abortion care provider of illegally profiting from sales.

The videos caught the attention of Republican lawmakers. Investigations by the House Energy and Commerce, House Judiciary, and Oversight and Government Reform committees found no wrongdoing. Further investigations into Planned Parenthood and fetal tissue transfer proceeded with the creation of the Select Investigative Panel on Infant Lives in October 2015, chaired by Rep. Marsha Blackburn (R-TN), leading to $1.59 million in spending and a 471-page final report making numerable anti-abortion recommendations.

Among those requests was a call for the government to ban fetal tissue research by government scientists, which Barack Obamas administration, which favored the practice, ultimately ignored.

Democrats on the committee released their own report, disputing the conclusions of their Republican colleagues. At the end of their crusade, the conclusion was undeniable: There was no wrongdoing on behalf of fetal tissue researchers, including Advanced Bioscience Resources, or anyone else in the fetal tissue research space, said Rep. Jan Schakowksy (D-IL), who served as the ranking Democrat on the select committee, in a statement to Rewire.News in October 2018.

Anti-abortion activists saw an opportunity to advance their agenda on fetal tissue research when President Donald Trump won election in 2016, but it took a conservative media freakout in 2018 to enact new restrictions.

Over the summer of 2018, conservative media focused on several transactions by Advanced Bioscience Resources, a company that procured fetal tissue from abortion providers and shipped it to researchers for use. ABR was also one of the subjects of the 2015 select committee investigation.

HHS decided to cancel the governments contract with ABR in late September 2018 and began a review of the agencys rules and processes for procuring fetal tissue for research. That review concluded last summer, with HHS announcing in June that it would ban any fetal tissue studies by in-house NIH scientists, like Hasenkrug. It also introduced strict paperwork requirements for any outside scientists conducting research funded by the government.

The decision came as welcome news to anti-abortion activists. The language is trying to hold an ethical standard for the research proposals and the research that might be done. The policy is not just about science. Its also about ethics, David Prentice, vice president and research director at the anti-abortion Charlotte Lozier Institute, told Science magazine last July.

For his part, Hasenkrug has reportedly asked the Trump administration several times for permission to begin working with UNCs humanized mice for a coronavirus cure, but is still waiting on permission. Per the Post:

On Feb. 19, two people said, Hasenkrug wrote to a senior NIH official, asking for permission to use those mice and run experiments related to covid-19. He eventually was told that his request had been passed on to senior HHS officials.

Since then, he has written repeatedly to NIH, laying out in greater detail the experiments he wants to undertake and why several alternatives to the fetal tissue-implanted mice would not be as useful. In one appeal to NIH, Hasenkrug wrote that the mice he was offered are more than a year old and have a relatively short time remaining to live, so they should be used quickly, according to Kerry Lavender, a Canadian researcher familiar with the correspondence.

Hasenkrugs request has reportedly been forwarded to the White House Domestic Policy Council, which is chaired by Trump himself, but the government has not made a decision on the research as of yet.

Read more here:
Coronavirus treatment research is delayed by Trumps ban on the use of fetal tissue - Vox.com

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

Even in the midst of the COVID-19 pandemic, cancer care must go on, but changes may need to be made in the way some care is delivered.

"We're headed for a time when there will be significant disruptions in the care of patients with cancer," said Len Lichtenfeld, MD, deputy chief medical officer of the American Cancer Society (ACS), in a statement. "For some it may be as straightforward as a delay in having elective surgery. For others it may be delaying preventive care or adjuvant chemotherapy that's meant to keep cancer from returning or rescheduling appointments."

Lichtenfeld emphasized that cancer care teams are going to do the best they can to deliver care to those most in need. However, even in those circumstances, it won't be life as usual. "It will require patience on everyone's part as we go through this pandemic," he said.

"The way we treat cancer over the next few months will change enormously," writes a British oncologist in an article published in the Guardian.

"As oncologists, we will have to find a tenuous balance between undertreating people with cancer, resulting in more deaths from the disease in the medium to long term, and increasing deaths from COVID-19 in a vulnerable patient population. Alongside our patients we will have to make difficult decisions regarding treatments, with only low-quality evidence to guide us," writes Lucy Gossage, MD, consultant oncologist at Nottingham University Hospital, UK.

The evidence to date (from reports from China in Lancet Oncology) suggests that people with cancer have a significantly higher risk of severe illness resulting in intensive care admissions or death when infected with COVID-19, particularly if they recently had chemotherapy or surgery.

"Many of the oncology treatments we currently use, especially those given after surgery to reduce risk of cancer recurrence, have relatively small benefits," she writes.

"In the current climate, the balance of offering these treatments may shift; a small reduction in risk of cancer recurrence over the next 5 years may be outweighed by the potential for a short-term increase in risk of death from COVID-19. In the long term, more people's cancer will return if we aren't able to offer these treatments," she adds.

One thing that can go on the back burner for now is routine cancer screening, whichcan bepostponed for now in order to conserve health system resources and reduce contact with healthcare facilities, says the ACS.

"Patients seeking routine cancer screenings should delay those until further notice," said Lichtenfeld. "While timely screening is important, the need to prevent the spread of coronavirus and to reduce the strain on the medical system is more important right now."

But as soon as restrictions to slow the spread of COVID-19 are lifted and routine visits to health facilities are safe, regular screening tests should be rescheduled.

The American Society of Clinical Oncology (ASCO) has issued new guidance on caring for patients with cancer during the COVID-19 outbreak.

First and foremost, ASCO encourages providers, facilities, and anyone caring for patients with cancer to follow the existing guidelines from the Center for Disease Control and Prevention (CDC) when possible.

ASCO highlights the CDC's general recommendation for healthcare facilities that suggests "elective surgeries" at inpatient facilities be rescheduled if possible, which has also been recommended by the American College of Surgeons.

However, in many cases, cancer surgery is not elective but essential, it points out. So this is largely an individual determination that clinicians and patients will need to make, taking into account the potential harms of delaying needed cancer-related surgery.

Systemic treatments, including chemotherapy and immunotherapy, leave cancer patients vulnerable to infection, but ASCO says there is no direct evidence to support changes in regimens during the pandemic. Therefore, routinely stopping anticancer or immunosuppressive therapy is not recommended, as the balance of potential harms that may result from delaying or interrupting treatment versus the potential benefits of possibly preventing or delaying COVID-19 infection remains very unclear.

Clinical decisions must be individualized, ASCO emphasized, and suggestedthe following practice points be considered:

For patients already in deep remission who are receiving maintenance therapy, stopping treatment may be an option.

Some patients may be able to switch from IV to oral therapies, which would decrease the frequency of clinic visits.

Decisions on modifying or withholding chemotherapy need to consider both the indication and goals of care, as well as where the patient is in the treatment regimen and tolerance to the therapy. As anexample, the riskbenefit assessment for proceeding with chemotherapy in patients with untreated extensive small-cell lung cancer is quite different than proceeding with maintenance pemetrexed for metastatic nonsmall cell lung cancer.

If local coronavirus transmission is an issue at a particular cancer center, reasonable options may include taking a 2-week treatment break or arranging treatment at a different facility.

Evaluate if home infusion is medically and logistically feasible.

In some settings, delaying or modifying adjuvant treatment presents a higher risk of compromised disease control and long-term survival than in others, but in cases where the absolute benefit of adjuvant chemotherapy may be quite small and other options are available, the risk of COVID-19 may be considered an additional factor when evaluating care.

For patients who are candidates for allogeneic stem cell transplantation, a delay may be reasonable if the patient is currently well controlled with conventional treatment, ASCO comments. It also directs clinicians to follow the recommendations provided by the American Society of Transplantation and Cellular Therapy and from the European Society for Blood and Marrow Transplantation regarding this issue.

Finally, there is also the question of prophylactic antiviral therapy: Should it be considered for cancer patients undergoing active therapy?

The answer to that question is currently unknown, says ASCO, but "this is an active area of research and evidence may be available at any time."

For more from Medscape Oncology, join us on Twitter and Facebook.

See the article here:
Disruptions in Cancer Care in the Era of COVID-19 - Medscape

As a partner, you will help the Arthritis Foundation provide life-changing resources, science, advocacy and community connections for people with arthritis, the nations leading cause of disability. Join us today and help lead the way as a Champion of Yes.

Our Trailblazers are committed partners ready to lead the way, take action and fight for everyday victories. They contribute $2,000,000 to $2,749,000

Our Visionary partners help us plan for a future that includes a cure for arthritis. These inspired and inventive champions have contributed $1,500,00 to $1,999,999.

Our Pioneers are always ready to explore and find new weapons in the fight against arthritis. They contribute $1,000,000 to $1,499,999.

Our Pacesetters ensure that we can chart the course for a cure for those who live with arthritis. They contribute $500,000 to $999,000.

Our Signature partners make their mark by helping us identify new and meaningful resources for people with arthritis. They contribute $250,000 to $499,999.

Our Supporting partners are active champions who provide encouragement and assistance to the arthritis community. They contribute $100,000 to $249,999.

Read more:
Arthritis Foundation | Symptoms Treatments | Prevention Tips ...

- Global Rheumatoid Arthritis Drugs Market Forecast 2020-2030

- Biologics, Non-Biologics, NSAIDs, sDMARDs and Others

LONDON, March 18, 2020 /PRNewswire/ -- The global Rheumatoid Arthritis market is estimated to have reached $58bn in 2018 and is expected to grow at a CAGR of 0.6% in the second half of the forecast period. In 2018, the biologics submarket held 85% of the global Rheumatoid Arthritis market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new236-page reportyou will receive180 tables and 121 figures all unavailable elsewhere.

The 236-page Visiongain report provides clear detailed insight into the rheumatoid arthritis market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.comor refer to our website: https://www.visiongain.com/report/global-rheumatoid-arthritis-drugs-market-forecast-2020-2030/#download_sampe_div

Report Scope

Global Rheumatoid Arthritis Marketforecast from 2020-2030

Revenue forecasts for theRheumatoid Arthritis Market by Drug Classfrom 2020-2030: Biologics Non-Biologics: NSAIDs, sDMARDs, Others

Revenue forecasts for theRheumatoid Arthritis Market by Drugsfrom 2020-2030: Humira Enbrel Remicade Rituxan/MabThera Simponi/Simponi Aria Orencia Actemra/Roactemra Cimzia Celebrex Xeljanz Arcoxia Others

Revenue forecasts for theRheumatoid Arthritis Market by Regionfrom 2020-2029: North America: U.S., Canada Europe: Germany, UK, France, Italy, Spain, Russia, Rest of Europe Asia-Pacific: Japan, China, India, Rest of Asia-Pacific Latin America: Brazil, Mexico, Rest of Latin America Middle East & Africa: Saudi Arabia, South Africa, Rest of MEA

Profiles of these selected leading companies: AbbVie Amgen, Inc. Bristol-Myers Squibb Eli Lilly and Company F. Hoffmann-La Roche Ltd Johnson & Johnson Merck & Co. Novartis AG Pfizer Sanofi S.A. UCB

Analysis of the Drivers, Restraints, Opportunities and Threats of the global rheumatoid arthritis drugs market

The report also includes SWOT Analysis of the Global rheumatoid arthritis drugs market

Key questions answered by this report: How is the Rheumatoid Arthritis drugs market evolving? What is driving and restraining the Rheumatoid Arthritis drugs market? What are the market shares of each segment of the overall Rheumatoid Arthritis drugs market in 2018? How will each Rheumatoid Arthritis drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030? How will the market shares for each Rheumatoid Arthritis drugs submarket develop from 2020 to 2030? Which individual therapies will prevail and how will these shifts be responded to? What will be the main driver for the overall market from 2020 to 2030? How will the market shares of the national markets change by 2030 and which geographical region will lead the market in 2030? Who are the leading players and what are their prospects over the forecast period? How will the industry evolve during the period between 2020 and 2030?

Story continues

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.comor refer to our website: https://www.visiongain.com/report/global-rheumatoid-arthritis-drugs-market-forecast-2020-2030/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.comto discuss any customized research needs you may have.

Companies covered in the report include:

4SCAbbVieAbivaxAblynx NV SanofiAdheron Therapeutics, Inc.Akari Therapeutics PlcAlder BiopharmaceuticalsAmgenAnacorAraim Pharmaceuticals, Inc.argenxArtax Biopharma, Inc.Astellas Pharma IncBaxalta IncorporatedBiocon Ltd.BiogenBioxpress TherapeuticsBoehringer IngelheimBristol-Myers SquibbCadila HealthcareCambridge Biotechnology Ltd.CASI PharmaceuticalsCatabasis PharmaceuticalsCelltex Therapeutics Corp.Celltrion, Inc.ChemoCentryxChugai Pharmaceutical Co., Ltd.Coherus BioSciences IncCovagen AGCyclacel PharmaceuticalsCyxone ABDaiichi SankyoDePuy SynthesDr Reddy's LaboratoriesEli LillyEpirus BiopharmaceuticalsFive Prime TherapeuticsFresenius KabiFujifilm CorporationGalapagos NVGaldermaGenentechGerresheimerGiaconda Ltd.Gilead Sciences, Inc.GlaxoSmithKline plcGlenmark Pharmaceuticals Ltd.Hanmi Pharmaceutical Co Ltd.HospiraImmunomedicsIncyte CorporationInnate Pharma - IPO PendingIntasItalfarmaco SpAIzana Bioscience Ltd.Janssen BiologicsJohnson & JohnsonKadmon HoldingsKyowa Hakko Kirin Co LtdLycera CorporationMedigeneMerck & Co.MesoblastMitsubishi Tanabe PharmaMomentaMorphosysMycenax BiotechMylan NVNeovacs SANeuBase Therapeutics, Inc.Novo NordiskOnyx Pharmaceuticals, Inc.OphthaliX, Inc. Can-Fite BioPharma LtdOutlook Therapeutics, Inc.PadlockPfizerPhilogen SpAPrincipia Biopharma, Inc.Protalex, Inc.Protalix BioTherapeuticsRa Pharmaceuticals Inc.Regeneron Pharmaceuticals, Inc.RocheSamsung BioepisSanofiShanghai CP Guojian PharmaceuticalsSpirig Pharma A.G.Takeda PharmaceuticalsTheravance Biopharma, Inc.TiGenix NV Takeda PharmaceuticalUCBVitaeris Inc,XencorXOMAZynerba Pharmaceuticals

Other Organisations Mentioned in the ReportAmerican College of RheumatologyNurses HealthWHONational Rheumatoid Arthritis SocietyUnited NationsUS Patent OfficeEuropean CommissionU.S. Food and Drug Administration (FDA)Committee for Medicinal Products for Human Use (CHMP)Centers for Disease Control and Prevention (CDC)World BankArthritis FoundationCanadian Arthritis SocietyWorld Arthritis DayNational Rheumatoid Arthritis SocietyServizio Sanitario Nazionale (SSN)Ministry of HealthNational Institute on AgingNational Center for Biotechnology InformationUnified Health SystemANVISA (Agncia Nacional de Vigilncia Sanitria)African League of Associations in RheumatologyInternational League of Associations for RheumatologyGovernment of Abu DhabiJohns HopkinsBumrungradCleveland ClinicVamedEmirates Arthritis FoundationNational Treasury of Republic of South AfricaEuropean Medicines AgencyNational Institute for Health Research (NIHR)National Institute for Health and Care Excellence (NICE)Institute for Quality and Efficiency in HealthcareInstitut fr Qualitt und Wirtschaftlichkeit im Gesundheitswesen IQWiG

To see a report overview please e-mail Sara Peerun on sara.peerun@visiongain.com

Related reports:

Global Bioreactors Market 2020-2030

Next-Generation Biologics Market Forecast to 2029

Global Biosimilars and Follow-On Biologics Market 2019-2029

Pharma Wholesale and Distribution Market Forecasts 2020-2030

Translational Regenerative Medicine Market Forecast 2020-2030

View original content:http://www.prnewswire.com/news-releases/visiongain-report-global-rheumatoid-arthritis-drugs-market-estimated-to-grow-at-a-cagr-of-0-6-in-the-second-half-of-the-forecast-period-301022961.html

SOURCE Visiongain

Read more:
Visiongain Report: Global Rheumatoid Arthritis Drugs Market Estimated to Grow at a CAGR of 0.6% in the Second Half of the Forecast Period - Yahoo...

Report Description

A recent market intelligence report that is published by Data Insights Partner on theglobal Rheumatoid Arthritis marketmakes an offering of in-depth analysis of segments and sub-segments in the regional and international Rheumatoid Arthritis market. The research also emphasizes on the impact of restraints, drivers, and macro indicators on the regional and global Rheumatoid Arthritis market over the short as well as long period of time. A detailed presentation of forecast, trends, and dollar values of global Rheumatoid Arthritis market is offered. In accordance with the report, the global Rheumatoid Arthritis market is projected to expand at a CAGR of 5% over the period of forecast.

Market Insight, Drivers, Restraints& Opportunity of the Market:

Rheumatoid arthritis is an autoimmune disease which can cause inflammation and pain in joints throughout the body. There are several types of diagnosis available for rheumatoid arthritis such as rheumatoid factor test, antinuclear antibody test, C-reactive protein test, erythrocyte sedimentation rate etc. Although there is no specific treatment available for cure of rheumatoid arthritis, some treatment help the patients to control this chronic disorder.

The global Rheumatoid Arthritis market is primarily driven by the increasing new cases of rheumatoid arthritis across worldwide. Around 1% of the world population has been suffering from rheumatoid arthritis whereas almost 3 new cases of rheumatoid arthritis per 10,000 population per year has been documented in 2018. In addition to increasing new cases of rheumatoid arthritis across worldwide, high diagnosis and treatment rate would likely to drive the global Rheumatoid Arthritis Market in the upcoming future. On the contrary, the stringent regulatory landscape and side effects of medications would likely to hamper the growth of the global Rheumatoid Arthritis market during the forecast period.

However, increasing expenditure in research and development, strategic alliance among key players and ongoing clinical trials may provide the global Rheumatoid Arthritis Market an opportunity to propel during the forecast period. For instance, Abbvie, a market leader in the global Rheumatoid Arthritis market acquired another pharmaceutical stalwart Allergan by US$ 63 Bn in June 2019. The acquisition would likely to boost the market position of Abbvie in the global Rheumatoid Arthritis market in upcoming future.

Request Preview of Report as Sample before Purchasing (For More Precedence Use Corporate email ID) :https://datainsightspartner.com/request-for-sample?ref=43

Segment Covered:

This market intelligence report on the global Rheumatoid Arthritis market encompasses market segments based on drug type and distribution channel. On the basis of drug type, the sub-market is categorized into NSAIDs, Analgesics, DMARDs, Glucocorticoids, Biologics, and Others. Based on distribution channel, the global Rheumatoid Arthritis market has been segregated into hospital pharmacies, retail pharmacies and drug stores and online sales. By Geography, the global Rheumatoid Arthritis market has been divided into North America (the U.S., Canada), Latin America (Brazil, Mexico, Argentina and other countries), Europe (Germany, France, the U.K., Spain, Italy, Russia, and other countries), Asia Pacific (India, Japan, China, Australia and New Zealand and other countries), Middle East and Africa (GCC, South Africa, Israel and Other countries).

Profiling of Market Players:

This business intelligence report offers profiling of reputed companies that are operating in the market. Companies such as AbbVie, Inc., Janssen Biotech, Inc., Amgen, Inc., Pfizer, Inc., Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol-Myers Squibb Company, and Eli Lilly and Company etc. have been profiled into detail so as to offer a glimpse of the market leaders. Moreover, parameters such as Rheumatoid Arthritis related investment & spending and developments by major players of the market are tracked in this global report.

Request for Report TOC:https://datainsightspartner.com/report/rheumatoid-arthritis-market/43#content

Report Highlights:

In-depth analysis of the micro and macro indicators, market trends, and forecasts of demand is offered by this business intelligence report. Furthermore, the report offers a vivid picture of the factors that are steering and restraining the growth of this market across all geographical segments. In addition to that, IGR-Growth Matrix analysis is also provided in the report so as to share insight of the investment areas that new or existing market players can take into consideration. Various analytical tools such as DRO analysis, Porters five forces analysis has been used in this report to present a clear picture of the market. The study focuses on the present market trends and provides market forecast from the year 2017-2027. Emerging trends that would shape the market demand in the years to come have been highlighted in this report. A competitive analysis in each of the geographical segments gives an insight into market share of the global players.

Find more research reports onHealthcare Industry,By Data Insights Partner

Salient Features:

This study offers comprehensive yet detailed analysis of the Rheumatoid Arthritis market, size of the market (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the period of forecast: 2019 2027, taking into account 2018 as the base year

It explains upcoming revenue opportunities across various market segments and attractive matrix of investment proposition for the said market

This market intelligence report also offers pivotal insights about various market opportunities, restraints, drivers, launch of new products, competitive market strategies of leading market players, emerging market trends, and regional outlook

Profiling of key market players in the world Rheumatoid Arthritis market is done by taking into account various parameters such as company strategies, distribution strategies, product portfolio, financial performance, key developments, geographical presence, and company overvie

Leading market players covered this report comprise names such as AbbVie, Inc., Janssen Biotech, Inc., Amgen, Inc., Pfizer, Inc., Novartis AG, Sanofi S.A., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Bristol-Myers Squibb Company, and Eli Lilly and Company. and among others

The data of this report would allow management authorities and marketers of companies alike to take informed decision when it comes to launch of products, government initiatives, marketing tactics and expansion, and technical up gradation

The world market for Rheumatoid Arthritis caters to the needs of various stakeholders pertaining to this industry, namely suppliers, manufacturers, investors, and distributors for Rheumatoid Arthritis market. The research also caters to the rising needs of consulting and research firms, financial analysts, and new market entrants

Research methodologies that have been adopted for the purpose of this study have been clearly elaborated so as to facilitate better understanding of the reports

Reports have been made based on the guidelines as mandated by General Data Protection Regulation

Ample number of examples and case studies have been taken into consideration before coming to a conclusion

Reasons to buy:

vIdentify opportunities and plan strategies by having a strong understanding of the investment opportunities in the Rheumatoid Arthritis market

vIdentification of key factors driving investment opportunities in the Rheumatoid Arthritis market

vFacilitate decision-making based on strong historic and forecast data

vPosition yourself to gain the maximum advantage of the industrys growth potential

vDevelop strategies based on the latest regulatory events

vIdentify key partners and business development avenues

vRespond to your competitors business structure, strategy and prospects

vIdentify key strengths and weaknesses of important market participants

Request for Report Analysis:https://datainsightspartner.com/report/rheumatoid-arthritis-market/43

See the original post:
RHEUMATOID ARTHRITIS MARKET size Surge at a Robust Pace in Terms of Revenue over 2027 - Packaging News 24

The right kind of inflammation is essential to your body's healing system. But chronic inflammation can be a problem.

Published: April, 2020

The saying "too much of a good thing" applies to much of life, but especially to inflammation.

"People think inflammation needs to be stomped out at all times, but it plays an essential role in healing and injury repair to keep your body safe and healthy," says Dr. Robert H. Shmerling, medical editor of Understanding Inflammation from Harvard Health Publishing and an associate professor of medicine at Harvard Medical School. "Some inflammation is good. Too much is often bad. The goal is to recognize when inflammation is simply doing its job, and when it can potentially cause problems."

Signs of inflammation are like a car's dashboard engine light. It tells you that something is wrong. But your response is not to take out the bulb, because that's not the problem. Instead, you look at what caused the light to turn on. "It's the same with inflammation," says Dr. Shmerling. "It's telling you that something bigger is going on that requires attention."

There are two types of inflammation: acute and chronic. People are most familiar with acute inflammation. This is the redness, warmth, swelling, and pain around tissues and joints that occurs in response to an injury, like when you cut yourself. When the body is injured, your immune system releases white blood cells to surround and protect the area.

"Acute inflammation is how your body fights infections and helps speed up the healing process," says Dr. Shmerling. "In this way, inflammation is good because it protects the body." This process works the same if you have a virus like a cold or the flu.

In contrast, when inflammation gets turned up too high and lingers for a long time, and the immune system continues to pump out white blood cells and chemical messengers that prolong the process, that's known as chronic inflammation. "From the body's perspective, it's under consistent attack, so the immune system keeps fighting indefinitely," says Dr. Shmerling.

When this happens, white blood cells may end up attacking nearby healthy tissues and organs. For example, if you are overweight and have more visceral fat cells the deep type of fat that surrounds your organs the immune system may see those cells as a threat and attack them with white blood cells. The longer you are overweight, the longer your body can remain in a state of inflammation.

Research has shown that chronic inflammation is associated with heart disease, diabetes, cancer, arthritis, and bowel diseases like Crohn's disease and ulcerative colitis.

Yet, because chronic inflammation can continue for a long time, it's not easy to know its exact impact. "It's a chicken-and-egg scenario," says Dr. Shmerling. "Does chronic inflammation increase the risk of these ailments, or is it a byproduct? It is not always clear."

Here are some other steps you can take to prevent and reduce chronic inflammation:

Most of the time, you don't need to worry too much about acute inflammation, says Dr. Shmerling. You can take an over-the-counter pain reliever to help relieve symptoms, or apply cold compresses to reduce swelling. "Otherwise, it is usually best to let the inflammation do its work to help with healing," says Dr. Shmerling.

Of course, the cause of acute inflammation may need treatment. For example, a bacterial infection may require antibiotics, so if you have a fever or significant symptoms such as severe pain or shortness of breath see your doctor.

Chronic inflammation is trickier to deal with. The problem is that chronic inflammation is often "invisible," since it does not show telltale physical signs the way acute inflammation does.

So how can you prevent or reduce inflammation you cannot necessarily see or feel?

The only way to detect chronic inflammation is to have an evaluation by your doctor. He or she will review your symptoms, perform a physical exam, and perhaps check your blood for signs of inflammation. (See "A test for inflammation.")

Otherwise, the best approach is to prevent conditions related to chronic inflammation. "It goes back to the basics: maintaining a healthy weight, choosing a good diet, getting plenty of sleep, and exercising regularly," says Dr. Shmerling.

How do you know if you have chronic inflammation? A blood test measures a protein produced by the liver, C-reactive protein (CRP), which rises in response to inflammation. A CRP level between 1 and 3 milligrams per liter of blood often signals a low, yet chronic, level of inflammation. The erythrocyte sedimentation rate is another blood test for inflammation. It is used for people with inflammatory conditions, like rheumatoid arthritis.

Diet and exercise have an especially strong impact on managing chronic inflammation since they both also can help control weight and improve sleep.

The evidence is not clear that a specific type of diet can prevent chronic inflammation. However, certain foods are associated with either promoting or inhibiting the inflammatory response. These foods also are linked to a lower risk of problems related to chronic inflammation, such as heart disease, weight gain, and cancer.

For instance, cut back or eliminate foods high in simple sugars like soda, fruit juices with added sugars, sports drinks, processed meat, and refined carbs like white bread and pasta. "These foods can spike blood sugar levels, which can lead to overeating and weight gain," says Dr. Shmerling.

Also, eat more foods high in the antioxidants known as polyphenols, which can lower inflammation. Examples include all types of berries, cherries, plums, red grapes, onions, turmeric, green tea, and dark green leafy vegetables like spinach and kale.

Regular exercise can help protect against conditions linked with chronic inflammation, especially heart disease and obesity. A 2017 study in Brain, Behavior, and Immunity found that just 20 minutes of moderate-intensity exercise (in this case, walking on a treadmill) can have an anti-inflammatory effect.

Image: Mingirov/Getty Images

Disclaimer:As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

The rest is here:
Understanding acute and chronic inflammation - Harvard Health

Life expectancy is defined as the number of years remaining for an individual or a group of people at a given age. Longevity refers to the characteristics of the relatively long-life span of some members of a population. A persons life span is thought be largely determined by the combined effects of genetics and environmental factors. No matter where you live in the world, adopting these five habits will ensure a long, healthy and disease-free life.

Eating healthily

Consuming a diet with a wide variety of plant foods, such as fruits, vegetables, nuts, seeds, whole grains and beans may increase a persons life longevity and reduce the risk of diseases.

Eating plenty of plant foods is likely to help a person live longer. In turn, reducing the amount of fat, refined carbohydrates, sugar and salt will also help to increase life.

The benefit of exercise is seen regardless of peoples weight, age, sex and health conditions such as heart disease and cancer.

Greater amounts of physical activity are associated with additional life expectancy gains.

Exercise helps a person breath better, reduces stress and gives people a more positive outlook to life, all of which increases life expectancy.

In fact, at the highest level of activity of 450 minutes of exercise per week equated to 4.5 extra years to ones life.

See the original post:
How to live longer: Five habits to adopt into your life to increase life expectancy - Express

Dr Sachin Mittal

Your immunity will be your biggest ally in the fight against coronavirus pandemic. A detailed analysis of the infection shows that those with underlying illness or weakened immunity are more susceptible to a worst outcome.

Immunity or immune system is our bodys ability to protect us against any type of illness or disease.

The immune system is not a single entity, an organ or a type of cell but a complex system with many components that create it, strengthen it or weaken it. The idea of having a stronger immunity is very desirable, so many people are running a random Google search to find ways to strengthen it.

Heredity and genetics also determine our immune system and that is something beyond our control. One must keep in mind there are no easy quick fix solutions but we can always work gradually to strengthen our bodys defence mechanism against any form of illness.

Heres how you can boost up your immune system:

Sleep like a baby

Dalai Lama once said sleep is the best meditation. We cannot underestimate the importance of recharging our batteries with a regular seven to eight hour sleep.

Greg McKeown, the author of bestseller Essentialism, calls it an asset that we need to protect.

Sleep helps restore our immune, nervous, skeletal and muscular systems.

Research shows that regular sound sleep is associated with longevity and sleep difficulties are associated with problems like depression, alcoholism, bipolar disorder but also a weakened immune system.

Smoking and substance abuse

Apart from increasing the risk of many cancers and heart diseases, smoking weakens immune system. Research shows that smoking not only decreases our adaptive and innate immune responses but also increases abnormal disease-causing immune response. So, it acts like a double-edged sword and kills our soldiers in the last line of defense against infection and illness. Excessive alcohol consumption is also detrimental. Both smoking and excessive alcohol consumption can damage the lungs and impact the mucosal immune system negatively. Mucosal immune system facilitates the body to identify pathogens and fight the infection. Thats the reason why alcohol or tobacco addicts fall prey to common cold or any form of viruses easily.

Stress

Mahatma Gandhi said: There is nothing that wastes the body like worry. Stress is another big culprit that weakens our immunity. Chronic stress leads to high levels of cortisol the stress hormone which interferes with T-cells (a type of blood cells important for immune response) and decreases production of protective antibodies, thus decreasing the bodys immune response. So, our body would perform well and heal well when it is not under stress. Lets take out some time everyday for meditation and breathing exercises, which are beneficial in lowering down our stress levels.

Eat well; exercise often

Immunity comes with fitness and balanced diet. A nutritious diet is vital. We should not eat just to fill our tummy or satisfy our palate but to nourish our body. As per My Plate nutrition guide, we should have half our plate filled up with fruits and vegetables and the remaining half should be divided into grains and proteins. Avoid any kind of fad or extreme diets. Equally important is staying physically active because that increases blood flow and recharges the white blood cells, which have the responsibility of searching and destroying the infection in the body.

Low to moderate exercise naturally lowers levels of stress hormone Cortisol and helps our immunity. Consistency and regularity matters a physical activity of minimum 30 to 45 minutes a day is recommended for 5 days a week for a healthy lifestyle.

Supplements

While there is a lot of hype surrounding the so-called immune boosters, the evidence backing them is scanty. Yes, we need to ensure theres no deficiency of significant vitamin or micro nutrient like zinc, iron, selenium, etc. If we have any, then replenishing them will be helpful, though a balanced diet takes care of our nutrition needs. Vitamin D, which we get from the sunlight, plays an important role in bodys immunity. Research shows that Vitamin D deficiency is associated with increased autoimmune diseases and higher chances of infection. So, getting some sunshine has real health benefits. Take expert help in its treatment as overenthusiastic supplementation and excess of it can have serious health consequences. If consuming any special foods for building immunity, have it in moderation. The bottom line is, there is no magic wand to enhance our immunity overnight. Work on your health holistically, and gradually you will be able to build up good immunity.

The writer is a Chandigarh-based endocrinologist

Go here to see the original:
Coronavirus: Immunity your best bet, build it up - The Tribune India

For Earth, bleak times lay ahead. TheCOVID-19 diseaseis known to cause respiratory illness and fever, but some extra symptoms sweeping across the globe right now seem to be stress, fear, and anxiety. To provide some light relief in these dark times, weve collated 15 of our favorite good news stories to remind you that not everything is awful. Hold tight everybody, 2021 will come eventually.

The Super Pink Moon is comingYou might be stuck at home as part of your self-isolation, but luckily the night sky is about to put on quite a show as April sees the return of the Super Pink Moon. Full moons happen every month and were given different names by the Native Americans to map out the year based on significant events that ran in tandem with the occurrence of a full Moon. Aprils is known as the pink moon because it appeared at the same time as pink spring flowers. This Aprils will be a Super Pink Moon as it is the second supermoon of the year, a term used to describe the slightly enlarged appearance of the Moon as its fully illuminated by the Sun due to Earths position between the two. Quarantine or no, if you've got access to a window you should be able to catch sight of this beauty on April 7 and when you do, think of all the other people looking up at the same moon. Self isolation doesn't mean you're alone.

Mice have been cured of diabetesAn astonishing discovery at the Washington University School of Medicine in St. Louis has revealed that human stem cells could be successfully engineered to cure diabetes in mice, offering an avenue of hope for the treatment of this debilitating disease. They used human pluripotent stem cells, cells that have the capacity to become any cell in the body, to create insulin-producing pancreatic beta cells. The engineered stem cells supplemented the diabetic mices inability to produce insulin, curing them of the disease for 9 months to a year before relapse occurred.

Theres a new green fuel in townHydrogen fuel was fast shaping up to be a hopeful route for a zero-emissions means of running things, but its costly production in terms of energy was affecting hopes for it being a sustainable resource. A team in Tokyo has now managed to refine the process to yield 25 times more hydrogen than previous methods all while using thrifty ingredients including light and a specific kind of rust. Combined with all the solar power breakthroughs currently occurring, green energy is on the up.

A crash course in what not to do, according to one Stanford University psychologist.

Babies love baby talkEven if it makes your skin crawl to hear adults cooing over little uns, it turns out babies across the globe are universally partial to baby talk. The news comes fromStanford psychologist Michael Frank who led the largeststudyto date looking at how the different ways adults speak is received by babies across the world. While all babies were fans, older babies liked it best and even showed a preference for baby talk in their native language as they likely recognized it most even if they couldnt speak it yet. The overall winner was oohs and coos, so think twice before scorning your new-parent friends for embarrassing you in public the babies have spoken.

Important change in the winds for HIV treatmentShortly after a UK man became the second person cured of HIV a fantastic breakthrough in the treatment of this once devastating disease theres more good news in the UK as PrEP, a preventative drug that prevents HIV infection, will finally be available nationwide on the NHS having already been made available in Scotland. After a 3-year study involving 20,000 participants, the drug will be made available to those at higher risk of exposure from April. PrEP is already available in the US and you can find PrEP providers near you here.

-

Plasters finally take a step towards racial inclusivityMajor UK superstore Tesco has taken the long-awaited step to introduce skin tone diversity into their range of bandaids. Previously, widely available bandaids, or plasters in the UK, have mainly catered to Caucasian individuals and the racial oversight was brought to light by a moving Tweet from Domonique Apollon in April 2019 after he wore a bandaid suitable for his skin tone for the first time. Longtime readers of Malorie Blackman's literary series Noughts and Crosseswill appreciate this poignant detail becoming a reality, as will those watching the current BBC dramatization available to watch via iPlayer in the US (excellent for those self-isolating).

Universal flu vaccine passes integral stageWatchers of the Pandemic documentary on Netflix (we wouldnt recommend catching up now if you missed it) may remember the plight of flu-fighting epidemiologists as the constantly shape-shifting nature of influenza meant strains were annually moving beyond existing vaccinations. Now, a universal vaccine is becoming a reality as for the first time a vaccine, called FLU-v, has been developed that can induce immune responses that last at least six months. Phase I and II of the clinical trial have been approved meaning its safety for use in human subjects and we hotly await what comes next for the groundbreaking vaccine.

Top marks for lights out in dark sky nationSometimes a bit of darkness can be a good thing, and when it comes to nighttime, the tiny South Pacific island of Niue tops the charts. The International Dark-Sky Association (IDA) is a non-profit working to protect our most precious natural spaces from light pollution, and this year chose Niue as the first entire country ever to be accredited as a Dark Sky Place. This classification recognizes responsible lighting policies that preserve the natural darkness of nighttime carrying with it endless benefits for the biological cycles of animals, plants and humans.

-

People hating on National Parks created beautiful artIn a glimmering example of you cant please everybody, artist Amber Share decided to take some of the best worst reviews of National Parks in America and turn them intotourism posters, showing that we can still make something funny in the face of people's negativity. You can see the whole collection on her Instagram account @subparparks, but a personal favorite has to be the above magnificent minimization of Yellowstone.

CRISPR may hold the key for curing genetic blindnessSurgeons at Oregon Health & Science Institute have attempted to use gene hacking to cure Leber congenital amaurosis, a genetic condition that leads to the onset of blindness in early childhood. By directly gene editing within the patients eye, researchers hope to ...take people who are essentially blind and make them see," according to researchers.

The Arctic seed vault in Svalbard is thrivingLast month saw an enormous glut of 60,000 seed samples added to the ever-growing collecting in the Svalbard Global Seed Vault. Tucked beneath a mountain in Norway's Svalbard archipelago, the initiative began with hopes to create a Noahs ark for plant diversity to protect our green spaces should a global catastrophe occur up top. The collection now includes 1.05 million seed varieties including the first-ever donation from an indigenous US tribe. Nicknamed the "Doomsday vault", we may need it sooner than thought.

Sea sponges can sneeze, and the footage is amazingThe aah and choo of asneezing sea spongehas been caught on camera for the first time and the recording is hilarious. Stumbled upon almost by accident, the discovery came about while researchers were observing sea cucumbers and sea urchins sniffing the sea floor. The video shows the two-part sneeze of a tulip-shaped sponge as it expands before contracting, expelling particles as it goes. Researchers arent yet sure what the sneezes are in response to. Lets hope its not a case ofthe suds.

Vernal equinox brings early springThe times might be dark but for the Northern hemisphere, the days wont be, as spring arrives on March 19, the earliest date in 124 years. The variation in the date is the result of leap years and daylight savings time. It should be noted this is the astronomical definition of spring, which refers specifically to the position of Earth's orbit in relation to the Sun, so perhaps dont expect to hear a gay little spring song in your garden just yet.

Its possible some dinosaurs could GLOW IN THE DARKA titillating discovery published in the journal Historical Biology recently revealed that some dinosaurs may have glowed in the dark thanks to ultraviolet fluorescing feathers and horns. Many extant bird species are tetrachromats, defined by a fourth cone in their retina that means they can see the UV spectrum. Co-author Jamie Dunning's work on the photoluminescence of puffin beaks under UV light inspired the questions, could dinosaurs have this too? We'd like the answer to be yes, please. The only thing cooler than dinosaurs is glow-in-the-dark dinosaurs.

If you need more positivity in your life right now, take a look at these ingenious social distancing moments from around the world that will restore your faith in humanity.

Read the original post:
15 Good News Stories To Tackle The COVID-19 Sadness - IFLScience

By Helmo Preuss Mar 16, 2020

Share this article:

CAPE TOWN - It was currently too early to tell what the economic impact on South Africa of the national emergency measures to combat the spread of the coronavirus would be, as the South African Reserve Bank (Sarb) has not yet met to consider a repo rate cut, nor has the Treasury yet announced any fiscal policy support measures.

Nonetheless the containment measures announced by the South African government on 15 March, as well as those of other countries, was likely to lead to a contraction in economic activity in both the current quarter and the second quarter, with some economists even saying that we could have a contraction in the full year for the first time since 2009.

Nedbank chief economist Nicky Weimar said she had already expected the economy to remain in recession in the first quarter prior to outbreak of COVID19 and the national emergency/disaster declaration.

The first quarter decline will now just be deeper and likely to extend into the early part of the second quarter. Thereafter some improvement off a low base is still possible, if the world and South Africa manage to stop the spread of the pandemic and manage to treat the ill effectively. Prior to the pandemic, we had GDP growth of 0.7% for this year, then we revised it to 0.3% after China & Italy imposed their lockdowns. We will now have to re-examine our forecasts, but the risk of the economy contracting over 2020 is very high, Weimar said.

In response to a question on what she expected from the SARBs Monetary Policy Committee (MPC) meeting this week, she said she was expecting a 150 basis points cut, as the US Federal Reserve had cut by that amount in the last fortnight.

John Ashbourne from the UK-based Capital Economics said it was too early to tell what the economic impact on South Africa of the national emergency measures to combat the spread of the coronavirus would be, but noted that the Treasury had limited fiscal maneuvering space.

For now, it seems like the economic effect will depend on how aggressive the containment measures are. In China - and, now, Italy - we have seen entire industries totally shut down. The Treasury just does not have a lot of firepower at the moment. From a stimulus perspective, I suspect that the SARB will have to act first. I am expecting a 50 basis points cut on Thursday, Ashbourne said.

He also expected a Moodys downgrade to junk status later in the year, but said it would have little impact.

The economic and financial dislocation caused by the virus will be much more significant than a downgrade, he added.

Bianca Botes, the Treasury Partner at Peregrine Treasury Solutions, said South Africa, in line with the rest of the world, was in for a rough ride that may take years to correct.

The national state of disaster of itself is not what will really impact economic growth, although funds that were budgeted for use elsewhere will now be redirected to assist in the management of the virus. The real economic impact will stem from the local and global viral fallout, and the fact that manufacturing, production and ultimately economic activity is grinding to a halt. The travel ban will also have adverse effects on our tourism industry. As a whole, South Africa, in line with the rest of the world, is in for a rough ride that may take years to correct, Botes said.

She said a Moodys downgrade has become more likely, as the reallocation of funds to manage the viral breakout, and the negative economic impact of the pandemic will have

adverse effects on the fiscal metrics and growth trajectory of South Africa.

In all likelihood, Treasury will look at easing tax in an effort to support business and consumers, although exactly what these tax cuts may look like is still uncertain. The SARB is likely to cut by at least 50 basis points given the economic challenges facing South Africa, with the Covid-19 outbreak exacerbating concerns especially given the fact that inflation is leaning towards the lower end of the band, leaving the central bank some room to ease rates somewhat aggressively, she concluded.

Stanford Mazhindu, the spokesperson of the trade union UASA said the school closures from Wednesday would have a major impact as there was a whole ecosystem that catered to school kids.

With schools being closed until after Easter, everyone in that chain will be affected including transportation people, people who sell food to them and students. Major events including the Jazz Festival in Cape Town have been cancelled. The impact this has on the finances of the organizers cannot be measured accurately right now, but there are big economic implications, Mazhindu said.

He was not sure whether Moodys would make a ratings decision at the end of March.

It might be that Moody's might decide not to rate South Africa or any other country for that matter while we are busy trying to contain the virus. Economic markets are struggling with a number of record breaking events taking place like the oil price crash, he noted.

The SARB at the moment would need to lower with at least 50 points. Bank of England and American Federal Reserve have lowered their policy rates in anticipation of the fall-out from the coronavirus and the low supply demand chain. We think the Reserve Bank should follow suit, he concluded.

BUSINESS REPORT ONLINE

View post:
How the national state of emergency will affect the economy - IOL

There is a close association between sarcopenia and diabetic peripheral neuropathy (DPN), according to study results published in Diabetes Research and Clinical Practice.

Sarcopenia may lead to reduced exercise and increased risk for microvascular complications in patients with diabetes mellitus, including nephropathy and retinopathy. Because there is little information on the association between sarcopenia and DPN, the goal of the current cross-sectional study was to explore this association. In addition, a cohort study was carried out to investigate the changes in muscle mass and nerve conduction velocity.

The cross-sectional study included 1794 individuals (937 men; mean age, 60.22 years). Of these, 183 patients (98 men; mean age, 59.08 years) were enrolled in the follow-up study with a median follow-up of 2.7 years.

All patients underwent nerve conduction tests and muscle mass index was calculated using the following formula: appendicular skeletal muscle mass (ASM; in kg) divided by height squared (HT2; in m2 [ASM/HT2]). The composite z scores for the sensory nerve conduction velocity (SCV) and motor nerve conduction velocity (MCV) were calculated. The changes in ASM/HT2, SCV, and MCV were calculated from the measurements approximately 2 years apart and changes in skeletal muscle were classified into 3 groups: a decrease in ASM/HT2 of >3%, a minor change within 3%, or an increase of >3%.

In men, the multivariate regression analysis showed that muscle mass index was positively associated with the median (=0.928; P <.001), ulnar (=1.462; P <.001), peroneal (=1.059; P =.001), and tibial MCV (=0.839; P =.001) among the motor neurons; the median (=1.499; P <.001), ulnar (=0.837; P =.044), peroneal (=2.090; P =.002), and sural SCV (=1.257; P =.014) among the sensory neurons; and the composite z scores of MCV (=0.197; P <.001) and SCV (=0.3000; P <.001).

Receiver operating characteristic analysis indicated that the optimal cutoff point for ASM/HT2 that indicated DPN was 7.09 kg/m2 (area under the curve, 0.605; 95% CI, 0.569-0.642; sensitivity, 53.1%; specificity, 72.3%).

No significant correlations were found between ASM/HT2 and MCV, SCV and neuropathy score, and DPN and sarcopenia in women.

In the follow-up cohort study, there was a strong positive association between 2-year changes in skeletal muscle and nerve conduction velocity. During the follow-up period, nerve conduction velocity increased in terms of the partial motor and sensory velocities with an increase in the muscle mass in men with diabetes. However, similar to the findings in the cross-sectional analysis, this phenomenon was generally not observed in women with diabetes.

The researchers noted several limitations to the study, including possible selection bias as the study was performed in a hospital and included mainly middle-aged adults with nonsevere diabetes. As such, the findings may not be generalizable to older patients.

The assessment of muscle mass may have clinical implications in the prevention of DPN in men with diabetes, concluded the researchers.

Reference

Zhang Y, Shen X, He L, Zhao F, Yan S. Association of sarcopenia and muscle mass with both peripheral neuropathy and nerve function in patients with type 2 diabetes [published online February 25, 2020]. Diabetes Res Clin Pract. doi:10.1016/j.diabres.2020.108096

This article originally appeared on Endocrinology Advisor

View post:
Close Association Between Diabetic Peripheral Neuropathy and Sarcopenia - Neurology Advisor

By Elizabeth Martin

More than 39 percent of the population will be diagnosed with cancer at some point in their life, so chances are, someone you know has had cancer. A 2019 study in JAMA Oncology found that acupuncture was significantly associated with lower pain levels for cancer patients. It seems that recently Eastern medicine, such as acupuncture, is integrating with Western medicine. The ongoing opioid crisis makes it more challenging to address cancer pain management, making acupuncture an alternative for pain.

One of the common side effects of chemotherapy is neuropathy, where nerve damage causes tingling, numbness and other sensations that can be extremely uncomfortable. This pain is often not treated or cant be treated with pain medication, but acupuncture proves to be a great alternative. Acupuncture and Chinese Medicine help open the body up and heal by promoting the flow of Qi (our vital energy). Acupuncture helps to bring circulation and blood flow to certain areas, helping the body to heal itself.

As a practitioner, I hear over and over that cancer patients are apprehensive about taking another medication for the side effects of another medication. But acupuncture is a noninvasive way to treat these side effects. I already mentioned that acupuncture helps with neuropathy because it stimulates blood flow to the damaged nerves. With nausea and loss of appetite, acupuncturists can open up channels that lead to the stomach meridian to help the body work more efficiently and improve the flow of energy to that area.

When someone has insomnia, its a sign that the brain is not shutting off. Acupuncture tells the neurotransmitters in the brain to calm down and helps to reprogram your bodys own circadian rhythm. When we are working on patients with insomnia, most of the time we choose to work on the heart meridians, because the heart calms the mind, and in traditional Chinese medicine we believe it is connected to the mind and spirit.

Often, schedules are packed with doctors appointments, but a visit to the acupuncturist is one to look forward to. I wanted my office to feel like home, so I purposely designed my practice to be that way, touching on the five elements of Chinese Medicine: wood, water, fire, earth, and metal and making it a tranquil, medical spa-like atmosphere. Doctors often look at their patients like a number, rushing to get them in and out of the door, but during an acupuncture appointment at our practice, we make a point to spend the time to get to know our patients and help to talk them through the emotions they may be going through during their cancer diagnosis and treatment.

Elizabeth Martin

The theory is that acupuncture is compared to going for a runincreasing circulation, draining the lymph nodes, and releasing toxins. Whenever you get acupuncture, it releases neurotransmitters in the brain like serotonin and epinephrine, which helps boost energy levels and improve mood. At the practice we also use acupuncture to help treat allergies, as it goes back to my earlier point about opening the flow of Qi.

With the treatments and appointments that many cancer patients are already going to, they can often be afraid and apprehensive to try acupuncture while in treatment. But in fact, this is the best time to go. We often hear from our cancer patients that they felt overwhelmed with adding another appointment, but after coming to acupuncture they felt more relaxed, had less pain, and felt calmer after undergoing regular acupuncture treatments. Often the patients that were skeptical of acupuncture would take a break and very often when stopping acupuncture regularly, it caused their pain to return.

Acupuncture is only one pillar of Chinese Medicine, but other modalities include manual therapy, Chinese herbal medicine, and meditation practices like Qi gong. A recent meta-analysis in patients with cancer and insomnia showed that yoga, meditation, hypnosis, mindfulness-based stress reduction, and qi gong have a moderate effect on the improvement of sleep quality for up to three months. At my practice, we also do sound healing classes, which has been a great way to start meditation and can help reduce stress. This practice uses vibrations (vocal or instrumental-like gongs, Tibetan singing bowls and tuning forks) in order to relax your mind and body.

Elizabeth Martin is a board-certified licensed acupuncturist. She is the owner of Hands On Acupuncture and Massage Therapy PC on Long Island. Visit http://www.handsonacupuncture.com to learn more.

See the rest here:
Six Benefits Of Acupuncture For Cancer Patients - Long Island Weekly News

With having published myriads of reports, Diabetic Peripheral Neuropathy Treatment Market Research imparts its stalwartness to clients existing all over the globe. Our dedicated team of experts deliver reports with accurate data extracted from trusted sources. We ride the wave of digitalization facilitate clients with the changing trends in various industries, regions and consumers. As customer satisfaction is our top priority, our analysts are available 24/7 to provide tailored business solutions to the clients.

In this new business intelligence report, Diabetic Peripheral Neuropathy Treatment Market Research serves a platter of market forecast, structure, potential, and socioeconomic impacts associated with the global Diabetic Peripheral Neuropathy Treatment market. With Porters Five Forces and DROT analyses, the research study incorporates a comprehensive evaluation of the positive and negative factors, as well as the opportunities regarding the Diabetic Peripheral Neuropathy Treatment market.

Request Sample Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2251608&source=atm

The Diabetic Peripheral Neuropathy Treatment market report has been fragmented into important regions that showcase worthwhile growth to the vendors Region 1 (Country 1, Country 2), region 2 (Country 1, Country 2) and region 3 (Country 1, Country 2). Each geographic segment has been assessed based on supply-demand status, distribution, and pricing. Further, the study provides information about the local distributors with which the market players could create collaborations in a bid to sustain production footprint.

The following manufacturers are covered:Achelios Therapeutics IncCelgene CorpCommence Bio IncGrunenthal GmbHImmune Pharmaceuticals IncKPI Therapeutics IncMedifron DBT Co LtdMitsubishi Tanabe Pharma CorpNovaremed LtdReata Pharmaceuticals IncRelief Therapeutics Holding AGViroMed Co Ltd

Segment by RegionsNorth AmericaEuropeChinaJapan

Segment by TypeAntimunocelASP-8477BNV-222CapsaicinCBX-129801Others

Segment by ApplicationHospitalClinicOthers

Make An EnquiryAbout This Report @ https://www.researchmoz.com/enquiry.php?type=E&repid=2251608&source=atm

What does the Diabetic Peripheral Neuropathy Treatment market report contain?

Readers can get the answers of the following questions while going through the Diabetic Peripheral Neuropathy Treatment market report:

And many more

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2251608&licType=S&source=atm

For More Information Kindly Contact:

ResearchMoz.com

Mr. Nachiket Ghumare,

90 State Street,

Albany NY,

United States 12207

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

Read more:
Diabetic Peripheral Neuropathy Treatment Market Industry Production and Demand, Competition News and Trends Forecasts to 2024 - Jewish Life News

Diabetic Neuropathy Market Research Report 2020, is mostly driven by the improved taking on of Diabetic Neuropathy across small and medium-sized enterprises. Worldwide Diabetic Neuropathy Market quantifying the talk on those players at the interval. The report figures the limits and strong points of the players. To begin with the Diabetic Neuropathy Market report which covers market characteristics, industry structure and comitative landscape, the problems, desire concepts, along with business strategies market effectiveness.

Ask For Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/213

About Diabetic Neuropathy Market Report

This research report categorizes the global Diabetic Neuropathy Market by players/brands, region, type and application. This report also studies the global market status, competition landscape, Market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porters Five Forces Analysis.

Market Competition by Top Key Players/Manufacturers:

Eli Lilly and Company, GlaxoSmithKline, Pfizer, Johnson & Johnson and Janssen Pharmaceuticals.

Download Free PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/213

Diabetic Neuropathy Market Dynamics in the world mainly, the worldwide 2020-2026 Diabetic Neuropathy Market is analyzed across major global regions. CMI also provides customized specific regional and country-level reports for the following areas:

Major Highlights of the Diabetic Neuropathy Market Report:

Diabetic Neuropathy Market Overview, Market shares and strategies of key players, Sales Market Forecast, Manufacturing Analysis of Diabetic Neuropathy, Market Driving Factor Analysis of Diabetic Neuropathy, Market Competition Status by Major Manufacturers, Upstream and Downstream Market Analysis of Diabetic Neuropathy, and Cost and Gross Margin Analysis of Diabetic Neuropathy.

Why This Report is Useful? It helps:

1. The report will include the qualitative and quantitative analysis with Diabetic Neuropathy Market estimation and compound annual growth rate (CAGR) between 2020 and 20262. Assess the Diabetic Neuropathy production processes, major issues, and solutions to mitigate the development risk.3. Comprehensive analysis of market dynamics including factors and opportunities of the global Diabetic Neuropathy Market will be provided in the report4. Insights from this report will allow marketers and management authorities of companies to make informed decisions with respect to their future product launch, technology upgrades, market expansion, and marketing tactics.

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/213

Further in the report, the Diabetic Neuropathy market is examined for Sales, Revenue, Price and Gross Margin. These points are analyzed for companies, types, and regions. In continuation with this data, the sale price is for various types, applications and regions are also included. The Diabetic Neuropathy industry consumption for major regions is given. Additionally, type wise and application wise figures are also provided in this report.

In this study, the years considered to estimate the market size of 2020-2026 Diabetic Neuropathy Market are as follows:History Year: 2015-2017Base Year: 2017Estimated Year: 2020Forecast Year 2020 to 2026

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Visit link:
Diabetic Neuropathy Market Application 2020 Industry Trends, Global Analysis, Business Growth & Demand, Top 5 Leading Players, Sectors &...

DOYLESTOWN, Pa., March 18, 2020 (GLOBE NEWSWIRE) -- Kannalife, Inc. (Kannalife or the Company) (KLFE), a biopharmaceutical med-chem company specializing in the research and development of potent novel monotherapeutics, announced today that the Company has been issued Australian Patent AU2015204609B2 (the Patent) specific to Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy. This patent grant marks the seventh patent that Kannalife has received to date on a worldwide basis.

Under the Patent, Kannalife will further explore the application and potential of new molecular entities (NMEs) across epilepsy, neuropathic pain, traumatic head injury, stroke, Chronic Traumatic Encephalopathy (CTE), Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, Epileptic Encephalopathy, and neurodegenerative diseases such as Parkinson's disease, Alzheimer's, Huntington's disease, and amyotrophic lateral sclerosis (ALS).

Australias pharma market is expected to reach $32.1 billion in 2020, according to data from research and consulting firm GlobalData.1

"We are pleased to see our IP estate recognized in Australia as novel and proprietary. We see this as an important first step towards commercializing our lead drug candidate KLS-13019 in that market in thefuture," said Dean Petkanas, CEO of Kannalife.

KLS-13019 leads Kannalifes intellectual property estate of novel, monotherapeutic molecules (KLS Family), which are capable of acting as neuroprotective agents and have the potential to treat a range of diseases, including nervous system, oxidative stress, and neurodegenerative disorders.

Of the seven patents issued to Kannalife on this technology, two are U.S. patents and five are foreign patents claiming priority to Kannalifes original 2014 U.S. filing date through international application PCT/US2015/010827, which was published as WO2015/106108A2 titled, "Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy (the PCT Patent). The seven patents consist of AU2015204609B2, and the following six patents:

The Company recently completed a STTR phase 1 study funded by a grant from the National Institutes of Healths National Institute on Drug Abuse. The study was performed in an animal model to evaluate the potential use of KLS-13019 as a potent, non-opioid alternative monotherapeutic in the prevention and reversal of chemotherapy-induced peripheral neuropathy (CIPN).

Kannalife also has national phase patent applications based on the PCT Patent application pending in Canada, Brazil and India.

About KLS-13019KLS-13019 is Kannalifes leading proprietary, investigational, novel, monotherapeutic product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. Its safety and efficacy have not been confirmed by FDA-approved research.

About Kannalife, Inc.Kannalife, Inc. is a biopharmaceutical med-chem company focused on the development of proprietary and patented novel monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders - including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.

The Company's KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

For more information about Kannalife, Inc., visit http://www.kannalife.com and visit the Companys Twitter page at @Kannalife.

Story continues

Forward-Looking StatementsThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This press release contains statements about expected future events, the Companys business plan, plan of operations, the viability of the Companys drug candidates, and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements, by definition, involve risks and uncertainties. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

References1. Drug Development & Deliver. Australias Pharma Sector to Grow to $32.1 Billionhttps://drug-dev.com/australias-pharma-sector-to-grow-to-32-1-billion/

CONTACT:

Public Relations:Andrew Hard, Chief Executive Officer of CMW MediaP: 888-829-0070E: andrew.hard@cmwmedia.com

Investor Relations: Scott Gordon, Managing Director of CORE IRP: 516-222-2560E: scottg@coreir.comwww.coreir.com

View post:
Kannalife, Inc. Receives Seventh Patent by Extending Patent Family to Australia for Its Novel Monotherapeutic Compounds to Treat CNS and PNS Disorders...

Three separate medical studies have found a potentially effective treatment for the coronavirus that could also be useful in preventing infections in some cases.

The coronavirus, known as COVID-19, is viewed as a particularly potent threat because there is currently no medical treatment and no preventative vaccine, so any hope of slowing down the spread and death rate could be significant.

What's the treatment? Multiple studies showed that the use of chloroquine to treat the coronavirus can lead to faster recovery and shorter hospital stays for patients.

Chloroquine is normally used as an anti-malarial drug, used for the prevention and/or treatment of malaria. It's available in the United States by prescription, and can be safely taken by men and women of all ages, including pregnant women.

Doctors in China and South Korea have observed that the coronavirus patients treated with chloroquine show reduced fever and better lung CT images, and so far research has not found any negative effects of the treatment.

From a study done in consultation with Stanford University School of Medicine, UAB School of Medicine, and the National Academy of Sciences:

UK catching on? The study noted that Europe may be aware of the potential use of chloroquine to treat coronavirus, shown by a recent move by the United Kingdom to add chloroquine to a list of medicines that can't be exported.

Read the original here:
Studies find potentially effective medicine for coronavirus treatment and prevention that's readily available - TheBlaze